The mitral valve sits between the left atrium and the left ventricle of the heart. With each heartbeat, it opens to move blood forward, then closes to stop blood from leaking backward. In degenerative mitral regurgitation (DMR), that valve gradually loses its ability to close properly, allowing blood to leak backward into the atrium. Over time, that leak can worsen, leading to symptoms like shortness of breath, fatigue and decreased ability to exercise. What makes DMR particularly frustrating is that it doesn’t progress at the same speed for everyone—and for some people, it eventually leads to surgery to repair or replace the valve.
A recent study on serotonin and heart valve disease suggests one possible clue as to why some people’s valves worsen more quickly: Serotonin signaling—best known for its role in mood and targeted by many antidepressants—may influence how quickly valve tissue deteriorates. In other words, serotonin-related biology could help explain why DMR progresses more quickly in certain people and may become a future target for better risk prediction or treatment of this disease.
The Clue From Real-World Patients: An SSRI Association in DMR
The recent study looked at a relatively large group of DMR patients who later underwent mitral valve repair or replacement. In this study, researchers found an association between SSRI use and the timing of surgery: Specifically, SSRI use was linked to needing surgery at a younger age. While this pattern is noteworthy, it should be interpreted with scientific caution because the evidence is observational. In other words, it shows that SSRI use and earlier surgery occur together, but it does not prove that SSRIs directly cause a faster progression of DMR in every patient. In addition, people who take SSRIs may differ from those who do not in other ways that could affect how heart disease progresses, even when statistical adjustments are made.
Still, observational findings are more convincing when they’re supported by biological experiments that suggest a plausible mechanism. In this recent study, the authors build on the idea of a link between SSRI use and quicker DMR progression by taking the “serotonin story” beyond what’s seen in patients and toward an explanation of how it might actually work biologically.
Why Serotonin Could Matter for Valve Remodeling
Serotonin is often described as a brain chemical, but it isn’t only used in the brain. It’s also a signaling molecule the body uses in many tissues, including in processes related to immune activity and tissue remodeling. That matters because the mitral valve is not just a static structure—it’s living tissue made up of cells that constantly respond to biological signals. Over time, those signals can influence how the valve’s structure changes.
In DMR, one of the most important parts of disease progression is remodeling. As DMR worsens, the valve tissue often becomes thicker and stiffer. A major contributor to these physical changes is a shift in how valve cells make structural proteins, especially collagen. When the balance of these proteins changes, the valve can gradually lose some of the flexibility it needs to work smoothly.
This is where the research focuses on fibrosis. Fibrosis is the formation of excess, scar-like tissue within an organ. When fibrosis develops in the mitral valve, the tissue typically becomes less elastic and more rigid. Since the mitral valve must open and close efficiently with each heartbeat, increased stiffness can make regurgitation more severe over time—helping the disease move forward rather than stabilize. Thus, if serotonin signaling influences the kinds of cellular behaviors that promote fibrosis and fibrotic remodeling, it creates a plausible biological pathway linking serotonin to DMR progression.
The Mechanism Focus: The Serotonin Transporter (SERT)
A central element in the recent study is the serotonin transporter, or SERT. You can think of SERT as part of the body’s system for tuning serotonin signaling: Its job is to help regulate how much serotonin remains available to activate receptors and trigger downstream cellular pathways. The research presents evidence that reduced SERT activity may promote valve remodeling in a pattern consistent with the progression seen in DMR.
In simplified terms, the logic is that SERT shapes serotonin signaling dynamics, changes in serotonin signaling can affect how valve cells behave and those altered cell behaviors can push the valve toward remodeling that aligns with worsening DMR. The story becomes even more compelling because the researchers connect these mechanistic ideas to genetics.
How a SERT Genetic Variant May Explain Why the Effect Isn’t the Same for Everyone
Individual biology varies, and some people naturally have different levels of SERT activity depending on their genetic makeup. In the recent study, the researchers describe a genetic region related to the serotonin transporter—referencing 5-HTTLPR—and report that a particular genotype, known as the “long-long” genotype, was associated with more severe valve progression.
The key takeaway isn’t the genetic detail itself, but what it enables the researchers to argue: If certain genotypes influence SERT activity, and different SERT activity states change how strongly serotonin signaling drives valve remodeling, then the observed connection between serotonin and SSRIs may not apply in the same way to every person. This is one reason genetics research often seems to unlock observational patterns—it can help explain why an effect might show up in a subset of patients rather than consistently across the entire group.
The Downstream Pathway: Collagen, Stiffness and Specific Receptor Signaling
Serotonin doesn’t act alone. It works by binding to different receptors, and those receptors can trigger different cellular programs. The recent study emphasizes that serotonin signaling appears connected to collagen production and valve stiffening/thickening—the kinds of physical changes that make DMR progression more likely.
It also highlights a particular serotonin receptor—HTR2B—as being important in the pathway toward damaging remodeling. In a scientific sense, focusing on a specific receptor is a big deal. It suggests researchers may not just be seeing serotonin involvement, but rather a more defined route that could potentially be targeted in future therapy development.
What This Study Can (and Can’t) Tell You About SSRIs and Heart Valves
Many headlines oversimplify medical findings, and when research links antidepressants to heart disease, the public message can quickly become alarmist. This new research does not support alarm-style conclusions such as “SSRIs worsen mitral valve disease,” “If you take an SSRI, your mitral valve will deteriorate faster” or “Stop your medication.” Even though the study finds an association between SSRI use and earlier surgery in patients with DMR, that does not prove that SSRIs directly cause faster valve damage.
The important scientific interpretation is that serotonin signaling may play a role in the remodeling process, and SSRI use could interact with the underlying serotonin biology of certain individuals. On a practical level, if you use an SSRI, the takeaway is not to change medication based on a single association study—antidepressant decisions should be guided by your overall mental health, symptom control and the advice of your clinician.
Changing DMR Care: Risk Prediction, Personalized Monitoring and Targeted Treatments
A helpful way to think about this new research is that serotonin may serve as a “remodeling signal.” In DMR, the mitral valve gradually shifts toward scarring and stiffness. The new research suggests that serotonin signaling could be one factor in that remodeling process—especially in people whose serotonin system is set up in a certain way genetically, and potentially in situations where SSRIs change serotonin signaling dynamics. So the takeaway is less about a simple cause-and-effect story like “antidepressants damage the mitral valve,” and more about a pathway model. In short, serotonin signaling may influence how valve tissue behaves as the disease degenerates.
Even if this new research doesn’t lead to immediate changes in patient decisions, studies like this can still influence how DMR care develops. It could improve risk prediction by identifying subgroups—using serotonin-related genetics—who are more likely to progress faster, allowing clinicians to refine risk estimates. It may also support more personalized follow-up: Since DMR monitoring depends on things like the severity of regurgitation and how the heart is coping, future biological markers could complement imaging and symptoms to guide who needs closer surveillance. Finally, it could enable more targeted therapies. If the harmful remodeling pathway involves specific receptors such as HTR2B, researchers could potentially design treatments that block that signaling route instead of broadly altering serotonin throughout the body.
Promising Implications for Serotonin Signaling and DMR Progression
The study suggests that serotonin signaling—shaped by the serotonin transporter (SERT), influenced by genetic variants and potentially modified by SSRI use—may be associated with more rapid progression of degenerative mitral regurgitation in certain patients. The study also points to a plausible mechanism involving fibrotic remodeling (including collagen-related changes) and highlights HTR2B as a potentially important receptor in that damaging pathway.
This is promising science, but it’s not a final instruction manual for patients. The message for the public is best framed as: Researchers are uncovering a more detailed biological map of DMR progression, and that map may eventually lead to better risk prediction and more tailored treatment strategies.
